Tags : Desidustat

Zydus to Initiate Clinical Study of Desidustat in Patients with

Tuba Khan July 24, 2020

Shots: Zydus has received the US FDA’s approval to initiate clinical trials of Desidustat in CIA. The company has initiated two P-III studies of desidustat The P-III DREAM-ND (NCT04012957) study […]readmore

Pharma

CMS Signs a License Agreement with Zydus for Desidustat in

Tuba Khan January 20, 2020

Shots: Zydus to receive up front, development & commercial milestones and royalties on sales of Desidustat while CMS to get a license to develop & commercialize the therapy for CKD […]readmore

Tags : Desidustat

Zydus to Initiate Clinical Study of Desidustat in Patients with

CMS Signs a License Agreement with Zydus for Desidustat in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Desidustat

Zydus to Initiate Clinical Study of Desidustat in Patients with

CMS Signs a License Agreement with Zydus for Desidustat in

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company